Axel Hauschild
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol 2022; 40:3741-3749.
16.06.2022Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
16.06.2022J Clin Oncol 2022; 40:3741-3749
Garbe Claus, Keim Ulrike, Amaral Teresa, Berking Carola, Eigentler Thomas Kurt, Flatz Lukas, Gesierich Anja, Leiter Ulrike, Stadler Rudolf, Sunderkötter Cord, Tüting Thomas, Utikal Jochen, Wollina Uwe, Zimmer Lisa, Zouboulis Christos C, Ascierto Paolo Antonio, Eggermont Alexander M M, Grob Jean-Jacques, Hauschild Axel, Sekulovic Lidija Kandolf, Long Georgina V, Luke Jason J, Michielin Olivier, Peris Ketty, Schadendorf Dirk, Kirkwood John M, Lorigan Paul C, Central Malignant Melanoma Registry (CMMR)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PloS one 2013; 8:e53745.
14.01.2013The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
14.01.2013PloS one 2013; 8:e53745
Voskens Caroline J, Mateus Christine, Mohr Peter, Paetzold Sylvie, Satzger Imke, Schadendorf Dirk, Schlaeppi Marc, Schuler Gerold, Schuler-Thurner Beatrice, Trefzer Uwe, Ulrich Jens, Vaubel Julia, von Moos Roger, Weder Patrik, Wilhelm Tabea, Göppner Daniela, Dummer Reinhard, Klein Christina, Keller Ullrich, Goldinger Simone M, Loquai Carmen, Robert Caroline, Kaehler Katharina C, Berking Carola, Bergmann Tanja, Bockmeyer Clemens L, Eigentler Thomas, Fluck Michael, Garbe Claus, Gutzmer Ralf, Grabbe Stephan, Hauschild Axel, Hein Rüdiger, Hundorfean Gheorghe, Justich Armin, Heinzerling Lucie M
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
von Moos R, Lademann J, Lacouture M, Dummer R, Lorusso D, Scotte F, Sehouli J, Harrold K, Rayson D, Aapro M, Thürlimann B, Hauschild A. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. EJO 2008; 44:781-90.
01.04.2008Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
01.04.2008EJO 2008; 44:781-90
von Moos Roger, Lademann Jürgen, Lacouture Mario E, Dummer Reinhard, Lorusso Domenica, Scotte Florian, Sehouli Jalid, Harrold Karen, Rayson Daniel, Aapro Matti, Thürlimann Beat, Hauschild Axel